These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7736528)

  • 21. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.
    Möbus VJ; Baum RP; Bolle M; Kreienberg R; Noujaim AA; Schultes BC; Nicodemus CF
    Am J Obstet Gynecol; 2003 Jul; 189(1):28-36. PubMed ID: 12861134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.
    Battaglia A; Fossati M; Buzzonetti A; Scambia G; Fattorossi A
    Immunol Lett; 2017 Nov; 191():35-39. PubMed ID: 28919454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma.
    Baum RP; Niesen A; Hertel A; Nancy A; Hess H; Donnerstag B; Sykes TR; Sykes CJ; Suresh MR; Noujaim AA
    Cancer; 1994 Feb; 73(3 Suppl):1121-5. PubMed ID: 8306256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3.
    Schmolling J; Reinsberg J; Wagner U; Krebs D
    Hybridoma; 1995 Apr; 14(2):183-6. PubMed ID: 7590777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice.
    Yuan W; Xia G; Zhao C; Sui C; Ma J
    Mol Med Rep; 2012 Feb; 5(2):388-94. PubMed ID: 22020296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
    Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
    Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
    Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
    Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
    Pfisterer J; du Bois A; Sehouli J; Loibl S; Reinartz S; Reuss A; Canzler U; Belau A; Jackisch C; Kimmig R; Wollschlaeger K; Heilmann V; Hilpert F
    Ann Oncol; 2006 Oct; 17(10):1568-77. PubMed ID: 17005631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Falsely low results in CA 125 determination due to anti-idiotypic antibodies induced by infusion of [131I]F(ab')2 fragments of the OC125 antibody.
    Reinsberg J; Nocke W
    Eur J Clin Chem Clin Biochem; 1993 May; 31(5):323-7. PubMed ID: 8357942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vivo study of antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].
    Chang XH; Cui H; Feng J; Yang WL; Li Y; Fu TY
    Ai Zheng; 2004 Jul; 23(7):777-81. PubMed ID: 15248911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a delivery system for the continuous endogenous release of an anti-idiotypic antibody against ovarian carcinoma.
    Hann E; Reinartz S; Clare SE; Passow S; Kissel T; Wagner U
    Hybridoma (Larchmt); 2005 Jun; 24(3):133-40. PubMed ID: 15943560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
    Grisham RN; Berek J; Pfisterer J; Sabbatini P
    Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours.
    Durrant LG; Doran M; Austin EB; Robins RA
    Int J Cancer; 1995 Mar; 61(1):62-6. PubMed ID: 7705934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Generation of genetic engineering anti-idiotypic antibody against OC125 monoclonal antibody of ovarian carcinoma].
    Zhang X; Cui H; Qian H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):646-8. PubMed ID: 9387521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor antibodies for immunotherapy of ovarian carcinomas.
    Wagner U
    Hybridoma; 1993 Oct; 12(5):521-8. PubMed ID: 8300125
    [No Abstract]   [Full Text] [Related]  

  • 36. Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique.
    Schlebusch H; Reinartz S; Kaiser R; Grünn U; Wagner U
    Hybridoma; 1997 Feb; 16(1):47-52. PubMed ID: 9085128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of monoclonal antibodies utilizing the host anti-idiotypic network.
    Hatzistilianou MN; Sivolapenko GB; Courtenay-Luck NS; Epenetos AA; Ritter MA
    In Vivo; 1995; 9(2):139-44. PubMed ID: 7548789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays.
    Oltrogge JB; Baum RP; Lema KN; Donnerstag B; Hör G
    Int J Biol Markers; 1997; 12(1):15-7. PubMed ID: 9176712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
    Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antigen mimicry of anti-idiotypic antibodies for human ovarian carcinoma antigen: generation and characterization of anti anti-idiotype antibodies].
    Lu WY; Qian HN
    Zhonghua Yi Xue Za Zhi; 1993 Oct; 73(10):581-3, 636. PubMed ID: 7508814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.